Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer

Seminars in Oncology

Volumn 24, Issue 5 SUPPL. 17, 1997, Pages

  Hortobagyi, G N ^a   Willey, J ^a   Rahman, Z ^a   Holmes, F A ^a   Theriault, R L ^a   Buzdar, A U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HEART; HEART FUNCTION TESTS; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; PROSPECTIVE STUDIES; STROKE VOLUME;

EID: 0030725307     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)